| Ytd | 192.75% | |
| 1y | 132.72% |
| Open | 10.26 | Prev Close | 10.35 | Low | 9.84 | High | 10.29 | Mkt Cap | 312.36M |
| Vol | 182.77K | Avg Vol | 457.23K | EPS | -1.44 | P/E | N/A | Forward P/E | -14.33 |
| Beta | 1.54 | Short Ratio | 10.24 | Inst. Own | 23.45% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 6.02 | 200-d Avg | 4.59 | 1yr Est | 16.81 |
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is re
Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let
AVITA Medical's reimbursement is now becoming more predictable. I believe this removes one of their
TD Cowen analyst Joshua Jennings maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the
BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price
Avita Medical NASDAQ: RCEL presented results from its PermeaDerm-I study, a randomized controlled tr
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product co
AVITA Medical's PermeaDerm study shows 70% lower product cost than allograft, with comparable clinic
Avita Medical NASDAQ: RCEL reported second-quarter 2026 revenue of $21.7 million, up 13% sequentiall
Avita Medical NASDAQ: RCEL expects continued sequential revenue growth and aims to reach cash flow b
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
VALENCIA, Calif., Aug. 09, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a
Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session.
VALENCIA, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a
Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The
Wall Street analysts upgraded AVITA, Etsy, Unity, and raised target prices for these stocks. See wha
BTIG analyst Ryan Zimmerman upgrades AVITA Medical (NASDAQ:RCEL) from Neutral to Buy and announce
Avita Medical NASDAQ: RCEL reported second-quarter 2026 revenue of $21.7 million, up 18% from a year
AVITA Medical, Inc. (RCEL) Q2 2026 Earnings Call Transcript
Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market
AVITA Medical (NASDAQ:RCEL) raises FY2026 sales outlook from $80.000 million-$85.000 million to $86.
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.25) per share which beat the analyst co
VALENCIA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a
Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and
ServiceNow Inc (NOW) rose in pre-market trading after reporting better-than-expected Q2 results. LGC
VALENCIA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“A
Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's afte
Avita Medical (RCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about t
First U.K. case series demonstrates successful use of RECELL GO® in 17 burn and reconstructive surge
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Prepared Remarks Transcript
AVITA Medical, Inc. (RCEL) Discusses Business Progress, Operational Changes and Sequential Revenue G
VALENCIA, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a l
Lake Street analyst Frank Takkinen upgrades AVITA Medical (NASDAQ:RCEL) from Hold to Buy and rais
AVITA Medical (NASDAQ:RCEL) affirms FY2026 sales outlook from $80.000 million-$85.000 million to $80
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.35) per share which missed the analyst
AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today
AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today
Agreement ensures rapid nationwide access to RECELL® for burn mass casualty incidents, providing BAR
Northland Capital Markets analyst Carl Byrnes initiates coverage on AVITA Medical (NASDAQ:RCEL) w
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maint
AVITA Medical (NASDAQ:RCEL) affirms FY2026 sales outlook from $80.000 million-$85.000 million to $80
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.38) per share which missed the analyst
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maint